| Market Cap | ₹6,823Cr |
| ROE | 11.72% |
| P/E Ratio(TTM) | 28.46 |
| EPS(TTM) | 26.45 |
| P/B Ratio | 3.33 |
| Dividend Yield | 0.66% |
| Industry P/E | 32.43 |
| Book Value | 225.73 |
| Debt to Equity | 0.32 |
| Face Value | 5 |
| Managing Director | Smt. Hetal Gogri Gala, Shri Narendra J. Salvi |
| Founded | 2019 |
| NSE Symbol | AARTIPHARM |
| FUND NAME | AUM(%) |
|---|---|
| ICICI Prudential Children's Fund Direct Growth | 0.50% |
| HDFC Multi Cap Fund Direct Growth | 0.16% |
| HDFC Large and Mid Cap Fund Direct Growth | 0.02% |
| COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
|---|---|---|---|---|
| JB Chemicals & Pharmaceuticals | NA (0.00%) | 39.11 | ||
| Emcure Pharmaceuticals | NA (0.00%) | 35.57 | ||
| Wockhardt | NA (0.00%) | -438.66 | ||
| Cohance Lifesciences | NA (0.00%) | 48.80 |